Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers ; volume:8 ; number:1 ; day:25 ; month:10 ; year:2008 ; pages:1-12 ; date:12.2008
BMC cancer ; 8, Heft 1 (25.10.2008), 1-12, 12.2008
- Creator
-
Toyama, Tatsuya
- Contributor
-
Yamashita, Hiroko
Kondo, Naoto
Okuda, Katsuhiro
Takahashi, Satoru
Sasaki, Hidefumi
Sugiura, Hiroshi
Iwase, Hirotaka
Fujii, Yoshitaka
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-8-309
- URN
-
urn:nbn:de:1111-2016030348098
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Toyama, Tatsuya
- Yamashita, Hiroko
- Kondo, Naoto
- Okuda, Katsuhiro
- Takahashi, Satoru
- Sasaki, Hidefumi
- Sugiura, Hiroshi
- Iwase, Hirotaka
- Fujii, Yoshitaka
- SpringerLink (Online service)
Other Objects (12)
Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development
The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice
BRCA1 mutation promotes sprouting angiogenesis in inflammatory cancer-associated fibroblast of triple-negative breast cancer
High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients
Frequently Asked Questions
Long-term oncologic outcomes of unselected triple-negative breast cancer patients according to BRCA1/2 mutations
A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both BRCA1 and BRCA2
Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study
A de Novo BRCA1 Pathogenic Variant in a 29-Year-Old Woman with Triple-Negative Breast Cancer
Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple‐Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy
Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple‐Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy
Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development
The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice
BRCA1 mutation promotes sprouting angiogenesis in inflammatory cancer-associated fibroblast of triple-negative breast cancer
High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients
Frequently Asked Questions
Long-term oncologic outcomes of unselected triple-negative breast cancer patients according to BRCA1/2 mutations
A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both BRCA1 and BRCA2
Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study
A de Novo BRCA1 Pathogenic Variant in a 29-Year-Old Woman with Triple-Negative Breast Cancer
Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple‐Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy
Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple‐Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy
Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development
The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice
BRCA1 mutation promotes sprouting angiogenesis in inflammatory cancer-associated fibroblast of triple-negative breast cancer
High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients
Frequently Asked Questions
Long-term oncologic outcomes of unselected triple-negative breast cancer patients according to BRCA1/2 mutations
A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both BRCA1 and BRCA2
Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study
A de Novo BRCA1 Pathogenic Variant in a 29-Year-Old Woman with Triple-Negative Breast Cancer
Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple‐Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy